Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma

Kurnit, Katherine C.; Sinno, Abdulrahman K.; Fellman, Bryan; Varghese, Aaron; Stone, Rebecca L.; Sood, Anil K.; Gershenson, David M.; Schmeler, Kathleen M.; Malpica, Anaís; Fader, Amanda N.; Frumovitz, Michael

doi:10.1097/aog.0000000000003579

Cited by 23 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, it compares tumor progression across three mucinous entities: adenoma, borderline, and invasive ovarian cancer. Second, our cohort included 40 of the rare mucinous ovarian neoplasms, which represents a large number of patients compared with other studies 26 27. Lastly, the inclusion of tumors with different grades and the nearly four decades of long-term follow-up enriches the quality of our analysis.…”

Section: Discussionmentioning

confidence: 99%

A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary

Chelariu-Raicu

Holley²,

Mayr³

et al. 2022

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

ObjectiveBecause mucinous carcinomas are rare tumors that affect several organ sites and are known to originate from different tissues, leading to frequent misdiagnoses, the objective was to characterize the differences between primary mucinous tumors of the ovary and metastatic mucinous cancer to the ovary by studying the expression pattern of several candidate biomarkers.MethodsTissue samples of mucinous histology were obtained between 1985 and 2015. Individual ovary and colon tissue samples were analyzed, including standard (PAX8, CK20, CK7, CDX2, SATB2, estrogen/progesterone) and new (MUC1, MUC5AC) biomarkers, which were then scored for immunoreactivity semi-quantitatively.ResultsThe study cohort included 98 mucinous tumor samples, including benign mucinous cystadenoma (n=24), mucinous borderline tumors (n=24), mucinous carcinomas (n=40), and metastatic mucinous ovarian carcinomas (n=10). A strong positive correlation was found between PAX8 scoring (p=0.003), CK7 scoring (p=0.0001), and MUC1 scoring (p=0.001) in primary mucinous ovarian cancer. Tumors of increasing invasiveness were analyzed and a significant decrease in the scoring of MUC5AC (p=0.001) was observed, with a stronger expression in adenomas (87%) and borderline tumors (75%), and a lower expression in mucinous cancers (42%). Patients survived significantly longer when their tumors expressed high PAX8 and showed an expansile invasion pattern (p=0.005 and p=0.015, respectively) compared with patients with PAX8-negative tumors and destructive invasion pattern.ConclusionThe study data support the diagnostic value of MUC1 as a new biomarker to differentiate between primary and metastatic mucinous ovarian cancer. In addition, the tumor growth pattern along with the PAX8 immunophenotype might represent potential prognostic biomarkers for primary mucinous ovarian carcinomas.

show abstract

Section: Discussionmentioning

confidence: 99%

A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary

Chelariu-Raicu

Holley²,

Mayr³

et al. 2022

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…Nonetheless, more than half of the enrolled patients so far were diagnosed with non-gynecologic mucinous carcinoma after the central review by pathologists. Kurnit et al [ 12 ] conducted a retrospective study to estimate whether gastrointestinal-type chemotherapy was associated with improved survival compared with standard gynecologic regimens for ovarian mucinous carcinoma patients. They found that gastrointestinal-type chemotherapy with or without bevacizumab improved survival in patients with ovarian mucinous carcinoma requiring adjuvant therapy.…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal-type chemotherapy prolongs survival in an atypical primary ovarian mucinous carcinoma: A case report

Wang

Niu

Feng

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND Primary ovarian mucinous carcinoma is a rare histologic subtype of epithelial ovarian carcinoma and exhibits considerable morphologic overlap with secondary tumour. It is hard to differentiate primary from metastatic ovarian mucinous carcinoma by morphological and immunohistochemical features. Because of the histologic similarity between primary ovarian mucinous carcinoma and metastatic gastrointestinal carcinoma, it has been hypothesized that ovarian mucinous carcinomas might respond better to non-gynecologic regimens. However, the standard treatment of advanced ovarian mucinous carcinoma has not reached a consensus. CASE SUMMARY A 56-year-old postmenopausal woman presented with repeated pain attacks in the right lower quadrant abdomen, accompanied by diarrhoea, anorexia, and weight loss for about 3 mo. The patient initially misdiagnosed as having gastrointestinal carcinoma because of similar pathological features. Based on the physical examination, tumour markers, imaging tests, and genetic tests, the patient was clinically diagnosed with ovary mucinous adenocarcinoma. Whether gastrointestinal-type chemotherapy or gynecologic chemotherapy was a favourable choice for patients with advanced ovarian mucinous cancer had not been determined. The patient received a chemotherapy regimen based on the histologic characteristics rather than the tumour origin. The patient received nine cycles of FOLFOX and bevacizumab. This was followed by seven cycles of bevacizumab maintenance therapy for 9 mo. Satisfactory therapeutic efficacy was achieved. CONCLUSION The genetic analysis might be used in the differential diagnosis of primary ovarian mucinous carcinoma and non-gynecologic mucinous carcinoma. Moreover, primary ovarian mucinous carcinoma patients could benefit from gastrointestinal-type chemotherapy.

show abstract

“…These women may derive more benefit from gastrointestinal-type chemotherapy regimens as compared with traditional carboplatin-based regimens. 27 , 28 …”

Section: Primary Treatmentmentioning

confidence: 99%

Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment

Kurnit¹,

Fleming²,

Lengyel³

2020

Obstetrics &Amp; Gynecology

Self Cite

218

137

View full text Add to dashboard Cite

show abstract

Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma

Abstract: Personal or nonessential information may be redacted at the editor's discretion.

Cited by 23 publications

References 18 publications

A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary

A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary

Gastrointestinal-type chemotherapy prolongs survival in an atypical primary ovarian mucinous carcinoma: A case report

Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment

Contact Info

Product

Resources

About